Form 4 for HCWB HCW Biologics Inc.
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-02 · accession 0001209191-22-055548 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-03 | 2022-11-02 | HCWB | Byam Rebecca | CFO | M - OptEx | $0.14 | +33.8K | 361.7K | +10% | +$4,725 |
| D | 2022-11-03 | 2022-11-02 | HCWB | Byam Rebecca | CFO | M - OptEx | $0.00 | -33.8K | 47.2K | -42% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-02 | M | A | 33,750 | $0.14 | 361,702 | D | — | — | |
| 2 | Derivative | Stock Option Grant (Right to Buy) | 2022-11-02 | M | D | 33,750 | $0.00 | 47,249 | D | $0.14 · — to 2029-12-19 | 33,750 Common Stock | (F1) These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant will vest on October 10, 2022; and 35% of the total shares subject to the stock option grant will vest on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement. |